Sunday, July 12, 2026

Pfizer Toxicologist’s Bombshell Testimony Rocks German Parliament : Elon Musk Says Vaccine Dose Left Him ‘Feeling Like Dying

Date:

A recent disclosure by a Swedish journalist on the social media platform X has triggered significant public discourse regarding the safety of COVID-19 vaccines. The journalist reported that a senior official from Pfizer admitted during a testimony to an inquiry commission that approximately 60,000 deaths may be attributable to the vaccine’s side effects. This shocking claim has yet to gain traction in mainstream media, which the journalist accuses of being tightly controlled by influential entities, including networks linked to Bill Gates and the pharmaceutical industry, thereby suppressing crucial information from the public.

Media Silence and Public Reaction

Despite the notable lack of coverage from traditional news outlets, the journalist’s tweet rapidly gained attention, amassing over 25 million views within six hours. This reflects a significant public interest and a burgeoning concern about vaccine safety. The discussion intensified further when Elon Musk shared the post, recounting his own negative experience following vaccination. Musk’s amplification contributed an additional 24 million views, escalating the already heated conversation into a more substantial global debate.

This situation extends beyond a simple public health issue; it raises critical questions about the control of information, narrative manipulation, and the systematic silencing of dissenting views. Such admissions, which have been overlooked by major publishers, call into question the broader implications of how information and public health discourse are managed. The experience of sudden cardiac events in vaccinated younger populations highlights the need for urgent and thorough investigations into the potential side effects of these vaccines.

The alarming patterns of adverse health events linked to COVID-19 vaccinations underscore the urgent need for transparent, independent investigation. The absence of an open dialogue on these pressing concerns has sparked calls for accountability. If pharmaceutical interests and their affiliated networks are influencing the information presented to the public, the implications extend into the realm of moral responsibility. It is suggested that every life lost and every question raised demands thorough scrutiny and action.

The messaging is clear: protecting human life should surpass the interests of profit or reputation. The ramifications of suppressing such critical information can no longer be dismissed as mere ignorance; they represent a profound complicity in the system that prioritizes convenience over truth.

Inquiry Background

Pfizer Toxicologist’s Bombshell Testimony Rocks German Parliament

In March 2026, Germany’s Bundestag hosted a parliamentary inquiry into the safety and efficacy of COVID-19 vaccines, prompted by ongoing public concerns over adverse events and data transparency. Dr. Helmut Sterz, a veteran toxicologist who served as Pfizer’s chief toxicologist for Europe until 2005, emerged as a key witness. His 30+ years at the company gave him insider knowledge of pharmaceutical testing protocols, making his statements particularly weighty.

Dr. Helmut testified that Pfizer’s mRNA vaccine (Comirnaty) bypassed standard toxicology testing required for novel products. He highlighted:

  • Lack of Preclinical Tox Studies: No comprehensive animal trials assessed lipid nanoparticle distribution or long-term toxicity before human rollout. “This was unprecedented,” Sterz stated, comparing it to routine drug development where such tests are mandatory.
  • Batch Variability: Internal data showed huge differences in adverse event rates across vaccine batches—some “hot lots” linked to severe reactions, while others were benign. He called this “a red flag ignored.”
  • Underreported Risks: Pfizer allegedly prioritized speed over safety, with mechanisms like the PREKINE study (a small Phase I trial) insufficient to catch organ accumulation of spike proteins or lipids.

These claims align with whistleblower documents and VAERS data analyses, which Dr. Helmut referenced, noting ratios of severe events up to 12:1 between high- and low-risk batches.

Dr. Helmut accused Pfizer of “scientifically untenable” shortcuts, urging independent batch testing. He criticized the EMA and Paul Ehrlich Institute for rubber-stamping approvals without demanding full tox data. “Patients were guinea pigs,” he said bluntly.

  • Carcinogenicity and Reproductive Toxicity Not Tested:
    • The carcinogenic risk of Comirnaty was not evaluated prior to approval due to time constraints.
    • No alternative studies were conducted to compensate for this omission.
    • A reproductive toxicity study on rats was poorly conducted, yielding unreliable data on effects during pregnancy and fetal development.
  • Accelerated Approval Process:
    • Approval was granted rapidly (“Schnelldurchgang”) according to the Robert Koch Institute (RKI) internal protocols.
    • Essential toxicological studies were sacrificed without valid justification.
    • Dr. Helmut states no comparable vaccine with a similar indication has been approved without these studies.
    • This expedited approval led to what the expert terms “illegal human experiments”.
  • Post-Marketing Safety Surveillance and Mortality Data:
    • Pfizer’s postmarketing report indicated over 1,200 suspected deaths within two months after approval.
    • The Paul Ehrlich Institute (PEI) received 2,133 death reports post-Comirnaty vaccination in Germany, but underreporting is significant.
    • In the U.S., an underreporting factor of about 30 is assumed; applying this to Germany suggests up to 60,000 vaccine-related deaths, though this figure is extrapolated and thus Not specified/Uncertain.
    • The German government withheld key safety and vaccination data from commissions, many of whom declined to request it.
  • Legal and Risk-Benefit Considerations:
    • Many vaccine-injured patients in Germany struggle to obtain compensation; courts often rule that Comirnaty has a positive benefit-risk ratio.
    • Clinical trials did not assess Comirnaty’s ability to prevent severe COVID-19 or death directly.
    • A mathematical estimate suggests that for every severe COVID case prevented, about 25 severe adverse reactions occur.
  • Mortality Trends:
    • Age-adjusted mortality in Germany increased in 2021 and 2022 compared to 2020, contradicting expectations if the vaccine were effective and safe.
  • Vaccine Composition and Manufacturing Concerns:
    • The vaccine tested in clinical trials was a highly purified substance too costly for mass production.
    • The widely distributed vaccine was produced using the bacterium Escherichia coli, resulting in significant contamination with bacterial DNA.
    • This contamination may contribute to a substantially increased cancer risk.

The testimony, livestreamed and widely shared online, has fueled calls for vaccine recalls, lawsuits, and a EU-wide audit. Opposition MPs hailed it as “explosive”.

This fits a pattern of 2026 revelations, including U.S. lawsuits against Pfizer for misrepresenting efficacy (95% claim based on relative risk reduction) and Finnish data showing excess mortality post-vaccination.

The revelations surrounding the possible side effects of the COVID-19 vaccine, alongside the media’s apparent reluctance to cover these stories, urge a reevaluation of the dynamics at play in public health decision-making. The public’s demand for truth and answers is rising, indicating a crucial moment in which ordinary citizens are seeking more transparent discourse regarding vaccine safety. It is imperative that stakeholders—governments, pharmaceutical companies, and media organizations—be held accountable for the information shared, as collective human life and wellbeing are at stake.

Also read:

Genetic Apocalypse: Pfizer’s mRNA Deception and the Threat to Humanity

The Trovan Case in Nigeria: Ethical Violations, Consequences, and Lessons Learned with Pfizer’s Experimental Drug

Landmark First Peer-Reviewed Study on Pfizer and Moderna Covid Vaccines Confirms ‘Excess Risk’ of Adverse Side Effects – Becker News

BREAKING: January 26, 2023, suggest that Pfizer is currently mutating COVID variants in order to produce vaccines for future sale.

Pfizer Caught Funnelling $12 Million to Anderson Cooper To Promote mRNA Jabs to Americans

Pfizer is sued by Texas over COVID-19 vaccine claims

Government Documents prove Bill Gates is Primary Funder of UK Medicine Regulator despite owning huge shares in Pfizer

 

Dr. Naomi Wolf Uncovers Pfizer’s Depopulation Agenda, as Evidenced by Its Own Documents

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Universal Health Organisation (UHO) Weekly Newsletter – 10 JULY 2026

Highlights: FDA, USA committee members on peptides have with conflicts of interest. Same dynamics operate in India’s Vaccine...

PM Modi outlined the Triple ‘T’ formula in New Zealand,

Prime Minister Narendra Modi addressed the gathering at a gala luncheon during his New Zealand visit. Beginning his...

There are suggestions for an alliance between the TVK, DMK, and Congress

Ahead of the monsoon session of Parliament, the political landscape between the government and the opposition is beginning...

Has your SIR form been submitted, or is it being held with the BLO

Currently, SIR work is underway in 16 states and three union territories. Have you completed your SIR form?...
news-1701

yakinjp

yakinjp

rtp yakinjp

yakinjp

yakinjp

yakin jp

yakinjp id

maujp

maujp

maujp

\

sabung ayam online

sabung ayam online

SLOT MAHJONG

sabung ayam online

invoice 00026

invoice 00027

invoice 00028

invoice 00029

invoice 00030

invoice 00031

invoice 00032

invoice 00033

invoice 00034

invoice 00035

invoice 00036

invoice 00037

invoice 00038

invoice 00039

invoice 00040

invoice 00041

invoice 00042

invoice 00043

invoice 00044

invoice 00045

invoice 00046

invoice 00047

invoice 00048

invoice 00049

invoice 00050

invoice 00051

invoice 00052

invoice 00053

invoice 00054

invoice 00055

article 2000021

article 2000022

article 2000023

article 2000024

article 2000025

article 2000026

article 2000027

article 2000028

article 2000029

article 2000030

article 2000031

article 2000032

article 2000033

article 2000034

article 2000035

article 2000036

article 2000037

article 2000038

article 2000039

article 2000040

article 2000041

article 2000042

article 2000043

article 2000044

article 2000045

article 2000046

article 2000047

article 2000048

article 2000049

article 2000050

article 2000051

article 2000052

article 2000053

article 2000054

article 2000055

article 2000056

article 2000057

article 2000058

article 2000059

article 2000060

article 2000061

article 2000062

article 2000063

article 2000064

article 2000065

article 2000066

article 2000067

article 2000068

article 2000069

article 2000070

article 2000071

article 2000072

article 2000073

article 2000074

article 2000075

article 2000076

article 2000077

article 2000078

article 2000079

article 2000080

pusdataru 00021

pusdataru 00022

pusdataru 00023

pusdataru 00024

pusdataru 00025

pusdataru 00026

pusdataru 00027

pusdataru 00028

pusdataru 00029

pusdataru 00030

pusdataru 00031

pusdataru 00032

pusdataru 00033

pusdataru 00034

pusdataru 00035

pusdataru 00036

pusdataru 00037

pusdataru 00038

pusdataru 00039

pusdataru 00040

pusdataru 00041

pusdataru 00042

pusdataru 00043

pusdataru 00044

pusdataru 00045

pusdataru 00046

pusdataru 00047

pusdataru 00048

pusdataru 00049

pusdataru 00050

pusdataru 00051

pusdataru 00052

pusdataru 00053

pusdataru 00054

pusdataru 00055

pusdataru 00056

pusdataru 00057

pusdataru 00058

pusdataru 00059

pusdataru 00060

article 00000031

article 00000032

article 00000033

article 00000034

article 00000035

article 00000036

article 00000037

article 00000038

article 00000039

article 00000040

article 00000041

article 00000042

article 00000043

article 00000044

article 00000045

article 00000046

article 00000047

article 00000048

article 00000049

article 00000050

article 00000051

article 00000052

article 00000053

article 00000054

article 00000055

article 00000056

article 00000057

article 00000058

article 00000059

article 00000060

article 00000061

article 00000062

article 00000063

article 00000064

article 00000065

article 00000066

article 00000067

article 00000068

article 00000069

article 00000070

article 00000071

article 00000072

article 00000073

article 00000074

article 00000075

article 00000076

article 00000077

article 00000078

article 00000079

article 00000080

pemohonan 000001

pemohonan 000002

pemohonan 000003

pemohonan 000004

pemohonan 000005

pemohonan 000006

pemohonan 000007

pemohonan 000008

pemohonan 000009

pemohonan 000010

pemohonan 000011

pemohonan 000012

pemohonan 000013

pemohonan 000014

pemohonan 000015

pemohonan 000016

pemohonan 000017

pemohonan 000018

pemohonan 000019

pemohonan 000020

pemohonan 000021

pemohonan 000022

pemohonan 000023

pemohonan 000024

pemohonan 000025

pemohonan 000026

pemohonan 000027

pemohonan 000028

pemohonan 000029

pemohonan 000030

artikel 000000081

artikel 000000082

artikel 000000083

artikel 000000084

artikel 000000085

artikel 000000086

artikel 000000087

artikel 000000088

artikel 000000089

artikel 000000090

artikel 000000091

artikel 000000092

artikel 000000093

artikel 000000094

artikel 000000095

artikel 000000096

artikel 000000097

artikel 000000098

artikel 000000099

artikel 000000100

artikel 000000101

artikel 000000102

artikel 000000103

artikel 000000104

artikel 000000105

artikel 000000106

artikel 000000107

artikel 000000108

artikel 000000109

artikel 000000110

artikel 000000111

artikel 000000112

artikel 000000113

artikel 000000114

artikel 000000115

artikel 000000116

artikel 000000117

artikel 000000118

artikel 000000119

artikel 000000120

pengadilan 000061

pengadilan 000062

pengadilan 000063

pengadilan 000064

pengadilan 000065

pengadilan 000066

pengadilan 000067

pengadilan 000068

pengadilan 000069

pengadilan 000070

pengadilan 000071

pengadilan 000072

pengadilan 000073

pengadilan 000074

pengadilan 000075

pengadilan 000076

pengadilan 000077

pengadilan 000078

pengadilan 000079

pengadilan 000080

pengadilan 000081

pengadilan 000082

pengadilan 000083

pengadilan 000084

pengadilan 000085

pengadilan 000086

pengadilan 000087

pengadilan 000088

pengadilan 000089

pengadilan 000090

perkara 0000066

perkara 0000067

perkara 0000068

perkara 0000069

perkara 0000070

perkara 0000071

perkara 0000072

perkara 0000073

perkara 0000074

perkara 0000075

perkara 0000076

perkara 0000077

perkara 0000078

perkara 0000079

perkara 0000080

perkara 0000081

perkara 0000082

perkara 0000083

perkara 0000084

perkara 0000085

perkara 0000086

perkara 0000087

perkara 0000088

perkara 0000089

perkara 0000090

article 0000021

article 0000022

article 0000023

article 0000024

article 0000025

article 0000026

article 0000027

article 0000028

article 0000029

article 0000030

article 0000031

article 0000032

article 0000033

article 0000034

article 0000035

article 0000036

article 0000037

article 0000038

article 0000039

article 0000040

article 0000041

article 0000042

article 0000043

article 0000044

article 0000045

article 0000046

article 0000047

article 0000048

article 0000049

article 0000050

article 0000051

article 0000052

article 0000053

article 0000054

article 0000055

article 0000056

article 0000057

article 0000058

article 0000059

article 0000060

article 0000061

article 0000062

article 0000063

article 0000064

article 0000065

article 0000066

article 0000067

article 0000068

article 0000069

article 0000070

article 3000031

article 3000032

article 3000033

article 3000034

article 3000035

article 3000036

article 3000037

article 3000038

article 3000039

article 3000040

article 3000041

article 3000042

article 3000043

article 3000044

article 3000045

article 3000046

article 3000047

article 3000048

article 3000049

article 3000050

article 3000051

article 3000052

article 3000053

article 3000054

article 3000055

article 3000056

article 3000057

article 3000058

article 3000059

article 3000060

news-1701